Alliance Pharma’s morning sickness drug gets marketing authorisation in the UK

03:25 EDT 6 Jul 2018 | Proactive Investors

The AIM-listed pharmaceutical company also said that the MHRA has approved the brand name Xonvea, which will be used for marketing Dicelctin in the UK

More From BioPortfolio on "Alliance Pharma’s morning sickness drug gets marketing authorisation in the UK"